Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | SCN7A | Q01118 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.54 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.52 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GABRD | O14764 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8358137 | 0.89 | SIGMAR1 (0.81) | SIGMAR1HPGDMKNK1MKNK2ALDH1A1 | |
| SCHEMBL208986 | 0.86 | HPGD (0.73) | SIGMAR1HPGDMEN1POLBKMT2A | |
| Piperazine SCHEMBL27980517 | 0.85 | HPGD (0.71) | SIGMAR1HPGDMEN1POLBKMT2A | |
| SCHEMBL15244760 | 0.85 | SCN9A (0.56) | SIGMAR1HPGDHRH3SCN7AKCNH2 | |
| SCHEMBL28156671 | 0.83 | SIGMAR1 (0.58) | SIGMAR1HPGDHRH3MKNK1MKNK2 | |
| SCHEMBL8260488 | 0.83 | SIGMAR1 (0.72) | SIGMAR1HPGDMEN1POLBKMT2A | |
| SCHEMBL3583338 | 0.83 | HPGD (0.73) | SIGMAR1HPGDMEN1KMT2AMKNK1 | |
| SCHEMBL5450590 | 0.82 | HRH3 (0.60) | SIGMAR1HPGDHRH3SCN7AKCNH2 | |
| SCHEMBL23140495 | 0.81 | SIGMAR1 (0.76) | SIGMAR1HPGDMKNK1MKNK2ALDH1A1 | |
| SCHEMBL4505138 | 0.81 | SIGMAR1 (0.70) | SIGMAR1HPGDMKNK1MKNK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111795-A1 | Multimers of Heterocyclic Compounds and Their Use | ARGENTA DISCOVERY LIMITED (GB) | 2009-04-30 | — | — | US | disclosed |
| US-20090111795-A1 | Multimers of Heterocyclic Compounds and Their Use | ARGENTA DISCOVERY LIMITED (GB) | 2009-04-30 | — | — | US | disclosed |
| US-20090105268-A1 | Dihydropyrimidone Multimers and Their Use as Human Neutrophil, Elastase Inhibitors | ARGENTA DISCOVERY LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| US-20090105268-A1 | Dihydropyrimidone Multimers and Their Use as Human Neutrophil, Elastase Inhibitors | ARGENTA DISCOVERY LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| WO-2006136857-A1 | DIHYDROPYRIMIDONE MULTIMERS AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | ARGENTA DISCOVERY LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105268-A1 | Dihydropyrimidone Multimers and Their Use as Human Neutrophil, Elastase Inhibitors | SERPINB1, ELANE, MPO | SIGMAR1 4501/4885HPGD 199/4885HRH3 1705/4885 |
| US-20090111795-A1 | Multimers of Heterocyclic Compounds and Their Use | MRM1, ME2, SDHA | SIGMAR1 3625/4885HPGD 193/4885HRH3 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.